# Intranasal trivalent candidate vaccine elicits broad humoral and cellular immunity against pneumococcal pneumonia

## TL;DR

A new trivalent vaccine targeting three pneumococcal proteins shows strong immune responses and improved protection against pneumococcal pneumonia in mice.

## Contribution

The trivalent vaccine targeting PepN, PepO, and SPD_1609 elicits broad immunity and superior protection compared to monovalent or bivalent vaccines.

## Key findings

- The trivalent vaccine induces robust humoral and Th1, Th2, Th17 cellular immune responses in mice.
- The vaccine significantly inhibits pneumococcal adhesion and reduces colonization and lung inflammation.
- The trivalent vaccine significantly increases survival rates in infected mice compared to other formulations.

## Abstract

Streptococcus pneumoniae is an important pathogen causing public health problems worldwide. Existing pneumococcal vaccines provide protection against only a few of the more than 100 pneumococcal serotypes, highlighting the urgent need for new preventive strategies. Pneumococcal protein vaccines have attracted considerable attention owing to their favorable immunogenicity and antigen conservation, and have demonstrated protective potential against non-serotype-dependent infections. Mice immunized with a trivalent vaccine targeting protein PepN, PepO, and SPD_1609 elicited a robust humoral immune response, as well as Th1, Th2, and Th17 cellular immune responses. The antiserum derived from the trivalent vaccine significantly inhibited Streptococcus pneumoniae adhesion to A549 cells, reduced pneumococcal colonization in the nasopharynx, and improved lung tissue damage and inflammatory responses compared to the monovalent or bivalent vaccine group. In terms of in vivo protection, the trivalent vaccine significantly increased the survival rate of infected mice. The findings suggest that the trivalent vaccine targeting PepN, PepO, and SPD_1609 is a promising multivalent vaccine candidate against Streptococcus pneumoniae.